Anti-CD44v7 Antibody, exon v7

CD44v7 (Approximant 200-250 kDa)

Recent studies indicate that the expression of CD44 on the cell surface changes profoundly during tumor metastasis, particularly during the progression of various carcinomas. Sequencing analysis reveals that CD44 exists in different forms (at least 15 isoforms have been identified) that are variants of the common or standard hemopoietic form CD44s. Specifically, the human CD44 gene contains 19 exons, out of which 10 exons can potentially be alternatively spliced. In particular, CD44s contains exons 1-15 and exons 15-19. The other exons (e.g. 6-14) are also spliced in a variety of different cells. For example, epithelial cells contain exons 12-14 inserted into the CD44s transcripts. This isoform has been designated as CD44E. Other CD44 variants CD44v) have the same sequences at the two ends of the molecule, but differ in a middle region (with different numbers of additional exons) located on the external side of the cell membrane. It has been suggested that expression of CD44 variants with the additional exon 11 (so-called v7) is responsible for tumor progression and metastasis. In fact, CD44v7 expression has been used as an indicator of metastasis

Epitope: exon v7

Synthetic peptide of human CD44v7

Detect CD44v7 using this Anti-CD44v7 Antibody, exon v7 validated for use in ELISA, FC, IP, WB, IC, IH(P).

ELISA: 1:1,000-1:2,000

Flow Cytometry: 1:500-1:1,000

Immunofluorescence: 1:100-1:200

Immunohistostaining of paraffin embedded tissue: 1:150-1:250

Immunoprecipitation: 1:100-1:200

Western Blotting: 1:5,000-1:10,000



Optimal working dilutions must be determined by the end user.

Replaces: 04-1123

Format: Purified

Purified immunoglobulin. Liquid in 10 mM sodium phosphate, pH 7.5 with 150 mM NaCl with 0.01% sodium azide.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany